Stockreport

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade) [Seeking Alpha]

Rhythm Pharmaceuticals, Inc.  (RYTM) 
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am Check Earnings Report
US:NASDAQ Investor Relations: ir.rhythmtx.com
PDF Imcivree shows promising Phase 2 results in treating hypothalamic obesity, potentially doubling its market if its Phase 3 trial proves successful. The company's finan [Read more]